This double-blind study to evaluate long-term efficacy and safety of atorvastatin was
performed in 31 community-and university-based research centers in the USA to directly …

Abstract By inhibiting 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase, the
statins reduce hepatocyte cholesterol levels, which results in up-regulation of low-density …

Abstract Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are the drugs
of choice in heterozygous familial hypercholesterolemia (FH), which has a high risk of …

Atorvastatin (Lipitor™, Pfizer) is a safe and effective 3-hydroxy-3-methyl-glutaryl-CoA (HMG-
CoA) reductase inhibitor (statin). It is the most potent currently available statin in terms of …

Background: Simvastatin and atorvastatin are effective statins for treating
hypercholesterolemia. Hypothesis: The study was undertaken to compare the efficacy and …

Background: Atorvastatin, a new enantiomerically pure synthetic statin, has shown a marked
low-density lipoprotein (LDL) cholesterol reduction at doses ranging from 10 to 80 mg/d …

The objective of this multicenter, randomized, open-label, parallel-group, 8-week study was
to evaluate the comparative dose efficacy of the 3-hydroxy-3-methylglutaryl coenzyme A …

Background The rate and degree of LDL cholesterol reduction, in the first 2 weeks of
therapy, may relate to the early benefit of hydroxymethyl glutaryl coenzyme A reductase …

This multicenter, double-blind, placebo-controlled, dose-response study was conducted in
patients with primary hypercholesterolemia to examine the effects of pravastatin, a selective …

Abstract This 6-week, double-blind clinical trial evaluated lipid parameter responses to
different dosages of atorvastatin in patients with primary hypercholesterolemia. Atorvastatin …